ABC transporter modulation: a strategy to enhance the activity of macrocyclic lactone anthelmintics

Trends in Parasitology

Volumn 24, Issue 7, 2008, Pages 293-298

  Lespine, Anne ^a   Alvinerie, Michel ^a   Vercruysse, Jozef ^b   Prichard, Roger K ^c   Geldhof, Peter ^b  

^a CEMAGREF   (France)

^b GHENT UNIVERSITY   (Belgium)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABAMECTIN; ABC TRANSPORTER; ANTHELMINTIC AGENT; DORAMECTIN; EPRINOMECTIN; FUMAGILLIN; GLYCOPROTEIN P; ITRACONAZOLE; IVERMECTIN; KETOCONAZOLE; LACTONE DERIVATIVE; LOPERAMIDE; MACROLIDE; MOXIDECTIN; MULTIDRUG RESISTANCE PROTEIN; QUERCETIN; SELAMECTIN; VALSPODAR; VERAPAMIL;

ARTICLE; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESEARCH; HUMAN; NONHUMAN;

ANIMALS; ANTHELMINTICS; ATP-BINDING CASSETTE TRANSPORTERS; DRUG RESISTANCE; HELMINTHS; LACTONES; MACROCYCLIC COMPOUNDS;

EID: 45449101104     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2008.03.011     Document Type: Article

References (50)

1. Kita K., et al. Advances in drug discovery and biochemical studies. Trends Parasitol. 23 (2007) 223-229
2. McKellar Q.A., and Benchaoui H.A. Avermectins and milbemycins. J. Vet. Pharmacol. Ther. 19 (1996) 331-351
3. Molyneux D.H., et al. Mass drug treatment for lymphatic filariasis and onchocerciasis. Trends Parasitol. 19 (2003) 516-522
4. Prichard R.K., and Roulet A. ABC transporters and beta-tubulin in macrocyclic lactone resistance: prospects for marker development. Parasitology 134 (2007) 1123-1132
5. McKellar Q.A., and Jackson F. Veterinary anthelmintics: old and new. Trends Parasitol. 20 (2004) 456-461
6. Carmichael I., et al. Haemonchus contortus resistance to ivermectin. J. S. Afr. Vet. Assoc. 58 (1987) 93
7. Kaplan R.M. Drug resistance in nematodes of veterinary importance: a status report. Trends Parasitol. 20 (2004) 477-481
8. Osei-Atweneboana M.Y., et al. Prevalence and intensity of Onchocerca volvulus infection and efficacy of ivermectin in endemic communities in Ghana: a two-phase epidemiological study. Lancet 369 (2007) 2021-2029
9. Besier B. New anthelmintics for livestock: the time is right. Trends Parasitol. 23 (2007) 21-24
10. Prichard R.K. Ivermectin resistance and overview of the consortium for anthelmintic resistance SNPs. Expert Opin. Drug Discov. 2 (2007) S41-S52
11. Kwei G.Y., et al. Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein. Drug Metab. Dispos. 27 (1999) 581-587
12. Schinkel A.H., et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77 (1994) 491-502
13. Kerboeuf D., et al. P-glycoprotein in helminths: function and perspectives for anthelmintic treatment and reversal of resistance. Int. J. Antimicrob. Agents 22 (2003) 332-346
14. Lankas G.R., et al. P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity. Toxicol. Appl. Pharmacol. 143 (1997) 357-365
15. Seaman J.T., et al. Avermectin B1 toxicity in a herd of Murray Grey cattle. Aust. Vet. J. 64 (1987) 284-285
16. Mealey K.L., et al. Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics 11 (2001) 727-733
17. Roulet A., et al. MDR1-deficient genotype in Collie dogs hypersensitive to the P-glycoprotein substrate ivermectin. Eur. J. Pharmacol. 460 (2003) 85-91
18. Lespine A., et al. Interaction of macrocyclic lactones with P-glycoprotein: structure-affinity relationship. Eur. J. Pharm. Sci. 30 (2007) 84-94
19. Lespine A., et al. Interaction of ivermectin with multidrug resistance proteins (MRP1, 2 and 3). Chem. Biol. Interact. 159 (2006) 169-179
20. Borst P., et al. The multidrug resistance protein family. Biochim. Biophys. Acta 1461 (1999) 347-357
21. Mealey K.L. Therapeutic implications of the MDR-1 gene. J. Vet. Pharmacol. Ther. 27 (2004) 257-264
22. Ballent M., et al. Modulation of the P-glycoprotein-mediated intestinal secretion of ivermectin: in vitro and in vivo assessments. Drug Metab. Dispos. 34 (2006) 457-463
23. Laffont C.M., et al. Intestinal secretion is a major route for parent ivermectin elimination in the rat. Drug Metab. Dispos. 30 (2002) 626-630
24. Hennessy D.R., and Alvinerie M.R. Pharmacocinetics of the macrocyclic lactones: conventional wisdom and new paradigms. In: Vercruysse J., and Rew R.S. (Eds). Macrocyclic Lactones and Antiparasitic Therapy (2002), CAB International 97-123
25. Lespine A., et al. The influence of parasitism on the pharmacokinetics of moxidectin in lambs. Parasitol. Res. 93 (2004) 121-126
26. Xu M., et al. Ivermectin resistance in nematodes may be caused by alteration of P-glycoprotein homolog. Mol. Biochem. Parasitol. 91 (1998) 327-335
27. Molento M.B., and Prichard R.K. Effects of the multidrug-resistance-reversing agents verapamil and CL 347,099 on the efficacy of ivermectin or moxidectin against unselected and drug-selected strains of Haemonchus contortus in jirds (Meriones unguiculatus). Parasitol. Res. 85 (1999) 1007-1011
28. Jones P.M., and George A.M. Multidrug resistance in parasites: ABC transporters, P-glycoproteins and molecular modelling. Int. J. Parasitol. 35 (2005) 555-566
29. Hong H., et al. Up-regulation of P-glycoprotein expression by glutathione depletion-induced oxidative stress in rat brain microvessel endothelial cells. J. Neurochem. 98 (2006) 1465-1473
30. Lincke C.R., et al. The P-glycoprotein gene family of Caenorhabditis elegans. Cloning and characterization of genomic and complementary DNA sequences. J. Mol. Biol. 228 (1992) 701-711
31. Nobili S., et al. Pharmacological strategies for overcoming multidrug resistance. Curr. Drug Targets 7 (2006) 861-879
32. Pouliot J.F., et al. Reversal of P-glycoprotein-associated multidrug resistance by ivermectin. Biochem. Pharmacol. 53 (1997) 17-25
33. Korystov Y.N., et al. Avermectins inhibit multidrug resistance of tumor cells. Eur. J. Pharmacol. 493 (2004) 57-64
34. Dupuy J., et al. Influence of verapamil on the efflux and metabolism of 14C moxidectin in cultured rat hepatocytes. J. Vet. Pharmacol. Ther. 24 (2001) 171-177
35. Dupuy J., et al. Enhancement of moxidectin bioavailability in lamb by a natural flavonoid: quercetin. Vet. Parasitol. 112 (2003) 337-347
36. Dupuy J., et al. The interaction between moxidectin and MDR transporters in primary cultures of rat hepatocytes. J. Vet. Pharmacol. Ther. 29 (2006) 107-111
37. Dupuy J., et al. Fumagillin, a new P-glycoprotein-interfering agent able to modulate moxidectin efflux in rat hepatocytes. J. Vet. Pharmacol. Ther. 29 (2006) 489-494
38. Alvinerie M., et al. Enhanced absorption of pour-on ivermectin formulation in rats by co-administration of the multidrug-resistant-reversing agent verapamil. Parasitol. Res. 85 (1999) 920-922
39. Lifschitz A., et al. Loperamide-induced enhancement of moxidectin availability in cattle. J. Vet. Pharmacol. Ther. 25 (2002) 111-120
40. Molento M.B., et al. Influence of verapamil on the pharmacokinetics of the antiparasitic drugs ivermectin and moxidectin in sheep. Parasitol. Res. 92 (2004) 121-127
41. Lifschitz A.L., et al. Loperamide modifies the tissue disposition kinetics of ivermectin in rats. J. Pharm. Pharmacol. 56 (2004) 61-67
42. Hugnet C., et al. Multiple oral dosing of ketoconazole increases dog exposure to ivermectin. J. Pharm. Pharm. Sci. 10 (2007) 311-318
43. Ballent M., et al. Involvement of P-glycoprotein on ivermectin kinetic behaviour in sheep: itraconazole-mediated changes on gastrointestinal disposition. J. Vet. Pharmacol. Ther. 30 (2007) 242-248
44. Karwatsky J., et al. A mechanism for P-glycoprotein-mediated apoptosis as revealed by verapamil hypersensitivity. Biochemistry 42 (2003) 12163-12173
45. Hammond C.L., et al. Glutathione export during apoptosis requires functional multidrug resistance-associated proteins. J. Biol. Chem. 282 (2007) 14337-14347
46. Synold T.W., et al. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat. Med. 7 (2001) 584-590
47. Schuetz E., and Strom S. Promiscuous regulator of xenobiotic removal. Nat. Med. 7 (2001) 536-537
48. Orlowski S., et al. P-glycoprotein and 'lipid rafts': some ambiguous mutual relationships (floating on them, building them or meeting them by chance?). Cell. Mol. Life Sci. 63 (2006) 1038-1059
49. Riou M., et al. Modulation of the multidrug resistance (MDR) system in the nematode Haemonchus contortus by changing cholesterol content: effects on resistance to anthelmintics. J. Antimicrob. Chemother. 52 (2003) 180-187
50. Bassissi M.F., et al. Influence of dyslipidemia on moxidectin distribution in plasma lipoproteins and on its pharmacokinetics. Pharm. Res. 23 (2006) 2672-2680